Ceribell, Inc. (CBLL) Financial Statements
Industry: Electromedical & Electrotherapeutic Apparatus
In fiscal 2025, Ceribell reported revenue of $89.1M, up 36.1% from $65.4M the year before. Net income was -$53.4M (a -60.0% net margin), or -$1.46 per diluted share. Gross margin was 87.9% and operating margin was -65.6%. Operating activities generated -$40.8M of cash, leaving -$41.6M of free cash flow. At fiscal year end, Ceribell held $195.8M in total assets against $40.5M in total liabilities, including $40.5M of cash and equivalents.
Open the full interactive Ceribell financials → Quarterly statements, key ratios, valuation history and price charts.
Ceribell Key Stats
| Share Price | $26.14 |
|---|---|
| Market Cap | $994.2M |
| Revenue YoY Growth | +36.1% |
| 52-Week Range | $10.92 – $26.14 |
| Shares Outstanding | 38.0 million (basic, 2026 Q2) |
Ceribell Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $65.4M | $89.1M |
| Gross Profit | $56.8M | $78.3M |
| Operating Income | -$39.7M | -$58.4M |
| Pre-Tax Income | -$40.5M | -$53.4M |
| Income Tax | — | $0 |
| Net Income | -$40.5M | -$53.4M |
| Diluted EPS | -$3.39 | -$1.46 |
Ceribell Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $22.6M | $24.8M | $26.5M | $28.1M |
| Net Income | -$13.5M | -$13.5M | -$19.7M | -$19.3M |
| Diluted EPS | -$0.37 | -$0.37 | -$0.52 | -$0.51 |
Ceribell Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $194.4M | $40.5M |
| Current Assets | $217.3M | $186.7M |
| Total Assets | $225.4M | $195.8M |
| Current Liabilities | $13.0M | $19.2M |
| Total Long-Term Debt | $19.6M | $19.8M |
| Total Liabilities | $34.2M | $40.5M |
| Shareholders' Equity | $191.2M | $155.3M |
Ceribell Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$35.0M | -$40.8M |
| Cash From Investing | -$1.6M | -$118.1M |
| Cash From Financing | $196.5M | $5.1M |
| Free Cash Flow | -$36.4M | -$41.6M |
Figures from Ceribell's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ceribell financials page for every line item.
Ceribell Company Profile
| Ticker | CBLL |
|---|---|
| Exchange | Nasdaq |
| Industry | Electromedical & Electrotherapeutic Apparatus |
| Headquarters | Sunnyvale, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001861107 |
Frequently Asked Questions
What was Ceribell's revenue in fiscal 2025?
Ceribell (CBLL) reported revenue of $89.1M for fiscal 2025.
What was Ceribell's net income in fiscal 2025?
Ceribell reported net income of -$53.4M for fiscal 2025.
What was Ceribell's earnings per share (EPS) in fiscal 2025?
Ceribell's diluted EPS was -$1.46 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ceribell generate in fiscal 2025?
Ceribell generated -$41.6M of free cash flow in fiscal 2025.
What was Ceribell's revenue last quarter?
In its most recent reported quarter (2026 Q2), Ceribell reported revenue of $28.1M.
How much debt does Ceribell have?
Ceribell reported $19.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Ceribell are outstanding?
Ceribell reported a weighted average of 38.0 million basic shares outstanding in 2026 Q2.
What is Ceribell's market cap?
Based on its latest closing price, Ceribell (CBLL) has a market capitalization of about $994.2M.
When does Ceribell's fiscal year end?
Ceribell's fiscal year end, as registered with the SEC, is December 31.
Where is Ceribell headquartered?
Ceribell lists its business address in Sunnyvale, California in its SEC filings.